Literature DB >> 7818925

Factors influencing survival of patients after radical surgery for gastric cancer. A regional study of 406 patients over a 10-year period.

A Arak1, K Kull.   

Abstract

The present retrospective report presents a review of prognostic factors influencing the survival of 406 gastric cancer patients radically operated on in the Tartu Oncology Hospital, Estonia in 1978-1987. All patients underwent total (n = 170) or subtotal (n = 236) gastrectomies with extensive lymphadenectomy (260 R2- and 146 R3-resections) according to the General Rules for the Gastric Cancer Study in Surgery and Pathology established by the Japanese Research Society for Gastric Cancer, introduced in our hospital at the end of the 1970s and now used as the unavoidable procedure for curative gastric cancer surgery. The 30-day postoperative mortality was 5.9% and the overall 5-year survival 46.1%. The male:female ratio was 0.95 and the mean age 62.4 years. Only 7.6% of all our patients operated on had early gastric cancer with a 5-year survival of 80.7% whereas 76.8% had T3-T4 tumours with a 5-year survival of 41.0%. Lymph node involvement was found in 44.6% of the patients. Independent favourable prognostic factors were (the 5-year survivals are presented within parentheses): limited (N0-N1) lymph node involvement (56.4 vs. 22.6%), pT 1-2 stage (62.8 vs. 41.0%), papillary, tubular or poorly differentiated histological pattern (51.9 vs. 33.1%), subtotal gastrectomy (55.9 vs. 32.4%) and age below 70 years (51.9 vs. 35.2%). Sex of patients, Borrmann type, size and site of tumour were not statistically associated with prognosis at multivariate analysis. Our results also suggested that besides predetermined prognostic factors, the surgical policy had a great impact on the prognosis of gastric cancer patients. We conclude that gastrectomy with combined resections of neighbouring organs directly invaded and with extensive lymphadenectomy at least up to the second node group might be the procedure of choice for advanced gastric cancer.

Entities:  

Mesh:

Year:  1994        PMID: 7818925     DOI: 10.3109/02841869409098456

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  4 in total

Review 1.  [Grading of tumors in the tubular digestive tract : Esophagus, stomach, colon and rectum].

Authors:  H Bläker
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

2.  Influence of pathological tumour variables on long-term survival in resectable gastric cancer.

Authors:  A Cuschieri; I C Talbot; S Weeden
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

3.  Development of novel HER2 inhibitors against gastric cancer derived from flavonoid source of Syzygium alternifolium through molecular dynamics and pharmacophore-based screening.

Authors:  Tirumalasetty Muni Chandra Babu; Aluru Rammohan; Vijaya Bhaskar Baki; Savita Devi; Duvvuru Gunasekar; Wudayagiri Rajendra
Journal:  Drug Des Devel Ther       Date:  2016-11-04       Impact factor: 4.162

4.  Molecular targeted agents for gastric cancer: a step forward towards personalized therapy.

Authors:  Esther Una Cidon; Sara G Ellis; Yasir Inam; Sola Adeleke; Sara Zarif; Tom Geldart
Journal:  Cancers (Basel)       Date:  2013-01-21       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.